0001855763-24-000004.txt : 20240510
0001855763-24-000004.hdr.sgml : 20240510
20240510163446
ACCESSION NUMBER: 0001855763-24-000004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240426
FILED AS OF DATE: 20240510
DATE AS OF CHANGE: 20240510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DOCHERTY JOHN MARTIN
CENTRAL INDEX KEY: 0001638727
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39874
FILM NUMBER: 24935519
MAIL ADDRESS:
STREET 1: 23 MIKELEN DRIVE
CITY: PORT PERRY
STATE: A6
ZIP: L9L 1V1
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lexaria Bioscience Corp.
CENTRAL INDEX KEY: 0001348362
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 202000871
STATE OF INCORPORATION: NV
FISCAL YEAR END: 0831
BUSINESS ADDRESS:
STREET 1: 100 - 740 MCCURDY ROAD
CITY: KELOWNA
STATE: A1
ZIP: V1X 2P7
BUSINESS PHONE: 250-765-6424
MAIL ADDRESS:
STREET 1: 100 - 740 MCCURDY ROAD
CITY: KELOWNA
STATE: A1
ZIP: V1X 2P7
FORMER COMPANY:
FORMER CONFORMED NAME: LEXARIA CORP.
DATE OF NAME CHANGE: 20080229
FORMER COMPANY:
FORMER CONFORMED NAME: Lexaria Corp.
DATE OF NAME CHANGE: 20051229
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0508
4
2024-04-26
0
0001348362
Lexaria Bioscience Corp.
LEXX
0001638727
DOCHERTY JOHN MARTIN
23 MIKELEN DRIVE
PORT PERRY
A6
L9L 1V1
ONTARIO, CANADA
1
1
0
0
President
0
common shares
54075
I
Private Holding Company
Stock Options
3
2020-04-23
2025-04-23
Common Shares
13334
13334
D
Stock Options
3
2021-04-26
2026-04-26
Common Shares
18000
31334
D
Stock Options
3
2021-06-08
2026-06-08
Common Shares
18334
49668
D
Stock Options
3
2021-09-01
2026-09-01
Common Shares
15000
64668
D
Stock Options
2.91
2022-08-29
2027-08-29
Common Shares
30000
94668
D
Stock Options
1.15
2023-10-26
2028-10-26
Common Shares
30000
124668
D
Stock Options
2.36
2024-04-26
4
A
0
49500
0
A
2024-04-26
2029-04-26
Common Shares
49500
174168
D
Repriced from $9.60 pursuant to shareholder approval received on May 9, 2023
Repriced from $5.31 pursuant to shareholder approval received on May 9, 2023
Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023
/John Docherty/
2024-05-10